company background image
BHVN logo

Biohaven NYSE:BHVN Stock Report

Last Price

US$54.69

Market Cap

US$4.7b

7D

-2.1%

1Y

299.8%

Updated

28 Mar, 2024

Data

Company Financials +

BHVN Stock Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.

BHVN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Biohaven Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biohaven
Historical stock prices
Current Share PriceUS$54.69
52 Week HighUS$62.21
52 Week LowUS$12.35
Beta0
1 Month Change14.75%
3 Month Change27.78%
1 Year Change299.78%
3 Year Changen/a
5 Year Changen/a
Change since IPO649.18%

Recent News & Updates

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Recent updates

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Dec 08

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Dec 04
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Sep 27

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Aug 28

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Jul 22
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Jun 14

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Jun 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Apr 06
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

Feb 21

Biohaven Ltd: Assessing The Spinoff

Dec 07

Biohaven Non-GAAP EPS of -$1.25

Nov 09

Shareholder Returns

BHVNUS BiotechsUS Market
7D-2.1%0.9%0.2%
1Y299.8%11.0%28.1%

Return vs Industry: BHVN exceeded the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: BHVN exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is BHVN's price volatile compared to industry and market?
BHVN volatility
BHVN Average Weekly Movement8.3%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BHVN's share price has been volatile over the past 3 months.

Volatility Over Time: BHVN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2022239Vlad Corichttps://www.biohaven.com

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson’s disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.

Biohaven Ltd. Fundamentals Summary

How do Biohaven's earnings and revenue compare to its market cap?
BHVN fundamental statistics
Market capUS$4.66b
Earnings (TTM)-US$408.17m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BHVN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$408.17m
Earnings-US$408.17m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BHVN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.